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EpitopeThe HLAMatchmaker algorithm, which allows the identiﬁcation of “safe” acceptable mismatches (AMMs) for
recipients of solid organ and cell allografts, is rarely used in part due to the difﬁculty in using it in the current
Excel format. The automation of this algorithm may universalize its use to beneﬁt the allocation of allografts.
Recently, we have developed a new software called EpHLA, which is the ﬁrst computer program automating
the use of the HLAMatchmaker algorithm. Herein, we present the experimental validation of the EpHLA pro-
gram by showing the time efﬁciency and the quality of operation. The same results, obtained by a single an-
tigen bead assay with sera from 10 sensitized patients waiting for kidney transplants, were analyzed either
by conventional HLAMatchmaker or by automated EpHLA method. Users testing these two methods were
asked to record: (i) time required for completion of the analysis (in minutes); (ii) number of eplets obtained
for class I and class II HLA molecules; (iii) categorization of eplets as reactive or non-reactive based on the MFI
cutoff value; and (iv) determination of AMMs based on eplets' reactivities. We showed that although both
methods had similar accuracy, the automated EpHLA method was over 8 times faster in comparison to the
conventional HLAMatchmaker method. In particular the EpHLA software was faster and more reliable but
equally accurate as the conventional method to deﬁne AMMs for allografts.
Conclusion: The EpHLA software is an accurate and quick method for the identiﬁcation of AMMs and thus it
may be a very useful tool in the decision-making process of organ allocation for highly sensitized patients
as well as in many other applications.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.olecular Biology Laboratory,
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The presence of anti-HLA antibodies in sera of solid organ trans-
plant recipients remains a well-documented risk factor for transplan-
tation [1]. Because of this, the development of methods to detect the
presence of anti-HLA antibodies has been a guiding motif for research
since the beginning of clinical transplantation. As a result of this ef-
fort, several methods have been developed including complement-
dependent cytotoxicity assay (CDC) [2], ﬂow cytometry crossmatch-
ing [3], as well as many solid phase assays (SPAs) [4]. One of the
solid phase assays uses multicolor beads, each coated with a single
class I or II HLA protein, to test previously sensitized patients' sera
231H.L.A.S. Filho et al. / Transplant Immunology 26 (2012) 230–234to identify: (I) allelic HLA speciﬁcities of preformed antibodies; and
(II) the relative reactivity patterns of these antibodies to deﬁne
their clinical importance [4]. While the high sensitivity of such
methods to detect very small quantities of anti-HLA antibodies
seems very attractive, the clinical interpretation of their impact on al-
lograft survival remains open. This is an especially pressing issue with
the rise in numbers of highly sensitized patients on waiting lists [5].
The actual challenge is to ﬁnd for each sensitized patient a matching
donor with acceptable HLA alleles (against which patient has no pre-
formed antibodies). To accomplish this goal, we need to identify a list
of unacceptable (with strong reactivity) and acceptable (with weak
or no reactivity) HLA alleles for each sensitized patient. Overall, the
objective is to increase the number of transplants for highly sensi-
tized patients without compromising the graft survival [6].
Another solution in the search for acceptable donors is the adop-
tion of a concept of acceptable mismatches (AMMs), which have
been extensively discussed elsewhere [7]. Indeed, the concept of
AMMs follows the assumption that the recognition of epitopes on
HLA molecules by antibodies occurs in discreet areas of the HLA mol-
ecules and some of these epitopes are identical on different HLAs [8].
Furthermore, since the patient's immune system is tolerant to self-
HLA molecules, all their epitopes may be designated as safe when
they are expressed on potential donor HLAs. Duquesnoy and his col-
laborators have described the sequences of polymorphic amino acid
residues in the areas of class I and II HLAmolecules, deﬁning function-
al epitopes and named them eplets [9,10]. This work has resulted in
the development of the HLAMatchmaker algorithm [11], which has
been validated by the Eurotransplant group and other centers
[12–14]. This program has resulted in an increased transplantation
rate among highly sensitized patients and a decreased waiting time
without compromising graft survival [15]. Such encouraging results
support a new paradigm, in which the search for epitope compatibil-
ity helps in the search for HLA molecules in the context of
transplantation.
The HLAMatchmaker algorithm is a powerful tool for determining
AMMs. However, despite this beneﬁt it is not universally used. A lim-
iting factor for using this tool is the difﬁculty in handling and inter-
pretation of often complex results. This is at least partly due to the
fact that many of the processing stages must be performed manually,
which is not only time-consuming but it increases the likelihood of
errors. We believe that the new paradigm of ﬁnding epitope-based
compatibility for highly sensitized patients needs to be developed as
a user-friendly tool that pinpoints strongly immunogenic as well as
weak and non-immunogenic epitopes on the HLA alleles. This
would enable to deﬁne better the immunological risk of transplanta-
tion. With this objective in mind, we have developed the EpHLA soft-
ware which automates many of the functions of the HLAMatchmaker
algorithm [16].
In the presented work we tested the ability of the EpHLA software
to determine HLA acceptable mismatches, in a timesaving way, re-
gardless of the user's background in immunogenetics. As it is the
case for every new automation tool, the EpHLA software was tested
for the minimum features that attest to software quality as required
by the ISO/IEC 9126-1 International Standard (Information
Technology-Software product quality-Part 1: Quality model; June/
1998). The tested features were those that are easily perceptible by
the users (e.g., functionality, reliability, usability, and efﬁciency).
Herein, we report an experimental validation aimed at testing the ca-
pacity of the EpHLA software in fulﬁlling these perceptible qualities.2. Objectives
To validate the EpHLA software by: (i) successfully categorizing
HLA molecules as AMMs or Unacceptable Mismatches (UMMs); and
(ii) to show the analysis is done with higher functionality, reliability,usability, and efﬁciency in comparison to the HLAMatchmaker algo-
rithm in its current Microsoft Excel format.
3. Methodology
3.1. Description of the EpHLA software and its functions
The EpHLA automation software (NIT 000083/2011, INPI Brazil) was
developed in the Object Pascal language. Its architecture enables the
automatic execution of the HLAMatchmaker algorithm; additionally, it
integrates public and private databases and reports to the user the
non-self eplets, AMMs, and UMMs for the analyzed recipient. Further,
the EpHLA software provides the calculated Panel of Reactive Anti-
bodies (cPRA) and the virtual cross-match results for the recipient/
donor pair. The input data for EpHLA include HLA allele typing, the ﬁle
with the SPA test data, and the cutoff MFI value [16].
3.2. Users who tested single antigen results
Eleven users with different expertise in HLAMatchmaker were in-
vited to evaluate single antigen results from 10 different HLA sensi-
tized patients waiting for a kidney transplant. All patients enrolled
in this study presented either class I or class II PRA higher than 61%,
a ﬁnding conﬁrmed by cPRA (ranging from 61% to 100%, obtained
by means of the Organ Procurement and Transplantation Network
tool (OPTN) [17]. Sera were tested using single antigen beads (One
Lambda, Canoga Park, CA) on the Luminex platform, according to
the manufacturer's instructions.
The HLA typings were carried out at medium-resolution using
sequence-speciﬁc oligonucleotide probe hybridization—SSOPH (One
Lambda, Canoga Park, CA, USA)—for the loci A, B and DRB1. HLA
alleles were inferred using the NMDP codes and the allele frequency
tables available at http://bioinformatics.nmdp.org/. The HLA alleles
of the loci DRB345, DQA1 and DQB1 were generated on the basis of
their linkage with the DRB1 alleles, using the HLAMatchmaker soft-
ware (DRDQ Allele Antibody Screen)—available at http://www.
hlamatchmaker.net/.
The users were divided according to their backgrounds in a con-
ventional HLAMatchmaker analysis into two groups: the ﬁrst experi-
enced group was composed of four technicians from Pontiﬁcal
Catholic University of Paraná with a modest amount of experience
using HLAMatchmaker during the last two years; the second non-
experienced group was composed of seven undergraduates from
Federal University of Piauí without any previous experience with
HLAMatchmaker or tissue typing training.
For the execution of this study, users from the experienced group re-
ceived additional training with the EpHLA software while users from
non-experienced group received training with the conventional HLA-
Matchmaker algorithm (implemented on an Excel electronic spread-
sheet) as well as in EpHLA software. Both groups were trained by the
same instructor and all users were asked to evaluate the same 10 single
antigen results using the HLAMatchmaker and EpHLA methods.
3.3. Analysis stages with the conventional and the automated methods
We provided users the same 10 Comma Separated Values (CSV)
ﬁles selected for experimental validation. A panel with Luminex
beads, each coated with different recombinant HLA molecules (97 al-
leles for class I with 1758 eplets and 91 alleles for class II with 2026
eplets), was represented in each CSV ﬁle. A full list of eplets are avail-
able at http://www.hlamatchmaker.net [18]. As previously explained,
it is important to emphasize that self-eplets were removed for each
patient from the eplets list for both conventional and automated HLA-
Matchmaker analysis as soon as the user enters the patient's HLA al-
leles. HLA alleles and number of non-self eplets for each patient are
shown in Tables 1 and 2.
Table 1
Class I HLA alleles and number of class I non-self eplets of 10 different HLA sensitized
patients.
Patient HLA-A* HLA-B* Nº non self eplets
1 02:01, 11:01 35:01, 39:01 614
2 24:02, 30:01 35:01, 42:01 630
3 01:01, 02:01 18:01, 40:02 741
4 02:01 39:02, 40:01 861
5 02:01, 30:02 15:03, 40:02 658
6 03:01, 32:01 07:02, 44:03 558
7 02:01, 74:01 48:01, 58:01 557
8 02:01, 11:01 07:02, 51:01 549
9 25:01, 31:01 15:01, 35:01 741
10 02:01, 31:01 27:03, 39:03 719
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egorized either as reactive or non-reactive based on the cutoff value
of the median ﬂuorescence intensity (MFI) value (herein calculated
as 500). Non-reactive eplets (assigned blue) were those appearing
in HLA alleles of the panel, which had an MFI value lower than the
cutoff value. In contrast, reactive eplets (assigned black) were those
appearing only in HLA alleles which had an MFI value higher than
the cutoff value. Overall, eplets categorized in this way were used
for the classiﬁcation of the HLA alleles into AMMs and UMMs. Users
considered all non-self HLA molecules composed of non-reactive
eplets and self-eplets as AMMs.
The next step was to compare the results of the conventional and
automated approaches. Just one eplet, with the same color, should ﬁll
correspondent positions in both results. When this rule is broken,
there is a disagreement in eplet categorization. A supportive program
was created to identify the number of these eplet disagreements be-
tween the conventional and automated analyses for each CSV ﬁle. It
ﬁltered all of the agreeing eplets and showed the number of eplets,
AMMs and disagreements in those variables. When disagreements
were found, the instructor was invited to critically review the case
in order to deﬁne whether the error leading to disagreement occurred
in the analysis of the single antigen results performed by the conven-
tional or automated method.
3.4. Quality features of the software veriﬁed in its validation
The four major perceivable features (functionality, reliability, us-
ability and efﬁciency) were tested to evaluate the quality of theTable 2
Class II HLA alleles and number of class II non-self eplets of 10 different HLA sensitized
patients.
Patient HLA-
DRB1*
HLA-
DRB3*
HLA-
DRB4*
HLA-
DRB5*
HLA-
DQA1*
HLA-
DQB1*
Nº non
self eplets
1 03:01,
04:07
02:02 01:01 – 05:01,
03:02
02:01,
03:01
398
2 01:01,
13:01
02:02 – – 01:01,
01:03
05:01,
06:03
550
3 04:04,
15:01
– 01:01 01:01 03:01,
01:02
03:02,
06:02
364
4 04:04,
11:01
02:02 01:01 – 03:01,
05:01
03:02,
03:01
325
5 11:01,
11:02
02:02 – – 05:01 03:01 679
6 01:01,
15:01
– – 01:01 01:01,
01:02
05:01,
06:02
581
7 01:01,
09:01
– 01:01 – 01:01,
03:02
05:01,
03:03
457
8 15:01,
16:01
– – 01:01,
02:02
01:02 06:02,
05:02
643
9 08:01 – – – 04:01 04:02 906
10 08:02,
15:01
– – 01:01 04:01,
01:02
04:02,
06:02
439EpHLA software. Functionality reﬂects the accuracy in accomplishing
the tasks for which the software was designed. Reliability refers to the
lack of failures in the software. Usability is an expression of use ade-
quacy as the software must be adequate to the type of user for
which it was designed. Thus, it is important that the user can easily
understand the concept and application of the program and can
learn how to use, operate, and control the tool. Efﬁciency expresses
the capacity of the software to obtain results quickly while using
few computer resources.
3.5. Statistical analysis
Differences in the time spent for the achievement of results using
conventional and automated HLAMatchmaker analysis was measured
using Student's t-test and the Mann–Whitney non-parametric test.
The disagreements analysis of the numbers of eplets and AMMs
among the users were evaluated using the likelihood ratio test after
Poisson distribution (H0; lambdab0.1 vs. H1; lambda ≥0.1). The sig-
niﬁcance levels for all of the tests were established at pb0.05.
4. Results
4.1. The time for training and the analysis time of the single antigen results
The non-experienced group required 60 training hours to be able to analyze single
antigen results with HLAMatchmaker using Microsoft Excel format. After this stage, ex-
perienced and non-experienced groups required 10 and 20 training hours, respective-
ly, to be able to use the EpHLA software.
The comparison of the average time spent in obtaining results from HLAMatch-
maker using the conventional and automated methods revealed that the EpHLA soft-
ware was almost 6 times faster when used by manual analysis experts (experienced
group) and over 10 times faster when used by users with low analysis experience
(Table 3, t-test, pb0.0001). The class II HLA analysis required a longer average time
to perform for both conventional (Table 3; t-test, pb0.002) and automated (Table 3;
Mann–Whitney, pb0.0001) programs when compared to the class I HLA analysis.
4.2. Assignment of the total numbers of eplets, AMMs, and disagreements
No difference in the number of non-self eplets was reported by users after both
types of analyses: it was counted a total of 72,908 non-self eplets in HLA class I and
58,762 non-self eplets in HLA class II. However, disagreements were observed with re-
spect to the categorization (colors) given to some eplets between the conventional and
automated methods. In fact, there was one disagreement for HLA class I and eleven dis-
agreements for HLA class II eplets. These twelve eplets were classiﬁed as reactive
(black) in the conventional analysis and as non-reactive (blue) in the automated anal-
ysis. As a consequence of such eplet categorization, twenty-one HLA alleles were con-
sidered UMMs, when using the conventional analysis, whereas they were classiﬁed as
AMMs when using the automated analysis. Due to these 21 AMMs' disagreements, the
number of HLA alleles considered AMMs in the conventional approach was 10,737,
however in the automated approach 10,758 HLA alleles were considered AMMs.Table 3
Time expressed in minute spent for the analyses of results obtained by single antigen
assays with conventional versus automated methods.
Testers'
groups
Method
Conventional Automated (EpHLA
HLA
Class I
HLA
Class II
HLA Class
I and II
HLA
Class I
HLA
Class II
HLA Class
I and II
EXPG
(n=40)
30.0±10.1 27.9±
8.7
57.9±13.6 4.5±1.5a 6.0±2.1a 10.5±
3.2a
NEXPG
(n=70)
37.7±14.2 49.8±
18.2
87.4±28.8 3.2±1.5a 5.2±2.2a 8.4±3.3a
All testers
(n=110)
34.9±13.3 41.8±
18.7 b
76.7±28.2 3.7±1.6a 5.5±2.2a 9.2±3.4a
Data are shown as average±standard deviation. Bold face represents signiﬁcant
values.
bcomparison between HLA inter class (Student t test) McDonald, J.H. 2009. Handbook
of Biological Statistics (2nd ed.). Sparky House Publishing, Baltimore, Maryland.
EXPG—experienced group
NEXPG—non-experienced group
a Comparison between HLA intra classes (Student t test).
233H.L.A.S. Filho et al. / Transplant Immunology 26 (2012) 230–234A closer examination of the above reported results revealed that there were errors
in eplets' categorization when using the conventional HLAMatchmaker analysis. In
particular, Fig. 1 shows a case with disagreements due to human error in conventional
analysis. The revised analysis permitted the correct categorization of eplets as non-
reactive and the respective HLA molecules as AMMs.
Fig. 1 shows screenshots of categorization eplets' disagreements between conven-
tional and automated HLAMatchmaker analysis.
The assigned cutoff was 500, alleles in bold were assigned was AMMs. The eplets
57PS and 125SH should be blue in conventional analysis (panel 1A), because they
are present on bead 47 with negative reaction of MFI=67 as shown by automated
analysis (panel 1B). Also, the allele DQB1*05:02 in conventional analysis should be in
bold (panel 1A), because it is an AMMwith blue non-self eplets as shown in automated
analysis (panel 1B).
4.3. EpHLA software and HLAMatchmaker algorithm produce similar outcomes in single
antigen results analyses
All disagreements identiﬁed in this study occurred due to human errors made by
the non-experienced group during the conventional HLAMatchmaker analysis. Howev-
er, the comparison between two methods showed no statistically signiﬁcant difference
for these variables (class I eplets, p=0.99; class I AMMs, p=0.85; class II eplets,
p=0.42 and class II AMMs, p=0.14). Thus, the EpHLA software accuracy was achieved
in executing the HLAMatchmaker algorithm as it did not make any system errors. The
same results suggest that although there was no statistical difference between twoBead ID DQB1 - DQA1 MFI
39 DQB1*02:01 - DQA1*02:01 1677 ,,
40 DQB1*02:01 - DQA1*03:01 938 ,,
41 DQB1*02:01 - DQA1*05:01 6419 ,,
42 DQB1*02:02 - DQA1*02:01 1221 ,,,,,4
43 DQB1*04:01 - DQA1*02:01 576 ,,23
44 DQB1*04:02 - DQA1*02:01 552 ,,,
45 DQB1*04:02 - DQA1*04:01 1547 ,,,
46 DQB1*05:01 - DQA1*01:01 0 ,14GL,,26G,30H
47 DQB1*05:02 - DQA1*01:02 67 ,14GL,,26G, 3
48 DQB1*06:01 - DQA1*01:03 10 3P
49 DQB1*06:02 - DQA1*01:02 62
50 DQB1*03:01 - DQA1*03:01 2356 ,14A
51 DQB1*03:01 - DQA1*02:01 3606 ,14A
52 DQB1*03:01 - DQA1*06:01 7086 ,14A
Self antigens Negative reac
Eplets Map - All mism
Allele MFI
DQB1*02:01-DQA1*02:01 1677 45GE5 56LPA 66DI
DQB1*02:01-DQA1*03:01 938 45GE5 56LPA 66DI
DQB1*02:01-DQA1*05:01 6419 45GE5 56LPA 66DI
DQB1*02:02-DQA1*02:01 1221 45GE5 56LPA 66DI
DQB1*04:01-DQA1*02:01 576 23L 26G 57LD
DQB1*04:02-DQA1*02:01 552 26G 57LD 66DI
DQB1*04:02-DQA1*04:01 1547 26G 57LD 66DI
DQB1*05:01-DQA1*01:01 0 14GL 26G 30HYV
DQB1*05:02-DQA1*01:02 67 14GL 26G 30HYV
DQB1*06:01-DQA1*01:03 10 3P3 14AM 26Y
DQB1*06:02-DQA1*01:02 26 SELF
DQB1*03:01-DQA1*03:01 2356 45EV
DQB1*03:01-DQA1*02:01 3606 45EV
DQB1*03:01-DQA1*06:01 7086 45EV
1A
1B
Conventional analys
Automated analysis:
14AM
14AM
14AM 26Y
26Y
26Y
Fig. 1. 1A Conventional analysis: DQB1 locus' patientmethods, even rare human errors in manual analysis can reduce the recipients’ chance
of transplantation or expose them to an unforeseen risk.
4.4. The EpHLA software fulﬁlls required quality of perceivable features for the user
As previously shown, the EpHLA software was capable of automatically executing
the HLAMatchmaker algorithm as accurately as the conventional manual method on an
Excel spreadsheet. Therefore, the EpHLA software fulﬁlled the functionality require-
ments because it accomplished the task to which it was designed with no errors in ap-
plying the algorithm. During a period of 3 months, the EpHLA software was
continuously used by 11 different users to perform analysis of 110 single antigen re-
sults. During this validation period there were no errors due to EpHLA software fail-
ures. Therefore, the automation tool enabled the performance of reliable
histocompatibility analyses.
The emerging results of this study make it evident that users with minimal knowl-
edge of the fundamentals about HLAMatchmaker are able to easily operate the EpHLA
software. It is noteworthy that the automation of manual steps enabled the user to
have a higher productivity in analyzing single antigen results. The decrease in the av-
erage time for this analysis was evidenced when users improved their skills with the
EpHLA software (Table 3).
The EpHLAprogramdoes not need a computerwith any special conﬁguration in order
to run. An adequate efﬁciency can be obtained when running on low-performance ma-
chines. During its validation, the EpHLA software was used in Core 2 Duo machines with
2 GBof RAM. In thesemachines the response for each input applied to the EpHLA softwareDQB1 non-self eplets  
,,,45GE5,,,,56LPA,,,66DI,,,,,77DR,,,,,,,,,,, 
,,,45GE5,,,,56LPA,,,66DI,,,,,77DR,,,,,,,,,,, 
,,,45GE5,,,,56LPA,,,66DI,,,,,77DR,,,,,,,,,,, 
5GE5,,,,56LPA,,,66DI,,,,,77DR,,,,,,,,135G,,, 
L,26G,,,,,,,57LD,,66DI,,70ED,,74SV,,,,,,,,,,,, 
26G,,,,,,,57LD,,66DI,,70ED,,74SV,,,,,,,,,,,, 
26G,,,,,,,57LD,,66DI,,70ED,,74SV,,,,,,,,,,,, 
YV,,57PV,,,,70GA,,74SV,77DR,,,87AY,,116I,125SQ,,,,, 
0HYV,,57PS,,70GA,,74SV,77DR,,,87AY,,116I,125SH,  
3,14AM,,26Y,,,,,,,,,66DI,,,,,,,,,,,,,,,167HG,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
M,,26Y,,45EV,,,,56PPD,,,,,,,,,,,,,,,,,,167HG, 
M,,26Y,,45EV,,,,56PPD,,,,,,,,,,,,,,,,,,167HG, 
M,,26Y,,45EV,,,,56PPD,,,,,,,,,,,,,,,,,,167HG, 
tions Positive reactions
atches,  Patient 3
77DR
77DR
77DR
77DR 135G      
66DI 70ED 74SV
70ED 74SV
70ED 74SV
57PV 70GA 74SV 77DR 87AY 116I 125SQ
57PS 70GA 74SV 77DR 87AY 116I 125SH
66DI 167HG
56PPD 167HG
56PPD 167HG
56PPD 167HG
is: DQB1 locus’s patient 3 
 DQB1 locus’s patient 3 
3. 1B Automated analysis: DQB1 locus patient 3.
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(a few milliseconds). Thus, the EpHLA software may perform all necessary operations on
standard computers.
5. Discussion
In spite of the ability of the HLAMatchmaker algorithm to improve
the allocation of solid organs for highly sensitized patients [15], the
widespread use of this tool is limited by the manually demanding and
time consuming intermediate steps. To solve this problem, we have de-
veloped a new software called EpHLA, which fully automates the func-
tional steps of the HLAMatchmaker algorithm [16]. The present study
has shown that the EpHLA software facilitates the identiﬁcation of
AMMs in a considerably shorter time while maintaining the same level
of accuracy when using the conventional HLAMatchmaker algorithm.
Since the EpHLA program is saving time and it is easy to use, we pre-
dict that it will have a signiﬁcant impact on the applicability of epitope-
based histocompatibility matches of donors for sensitized recipients.
The EpHLA program is also very useful to interpret antibody-mediated
rejections by identifying immunogenic epitopes. For these reasons, the
speed of generating results and their accuracy have gained great impor-
tance [19]. The expectation is that the EpHLA software will not only re-
duce the necessary time for case analysis, but also its user friendly
nature will popularize the clinical application of the HLAMatchmaker
algorithm. Hence, the time optimization obtained with EpHLA program
will allow for strategies similar to the Acceptable Mismatch Program of
Eurotransplant to be applied in other transplant programs. This will
beneﬁt the steadily growing numbers of highly sensitized patients
(PRAs >85%) enrolled in multiple transplant programs.
Another advantage for using the EpHLA software is the elimina-
tion of human errors. The results of this study demonstrate that infre-
quent disagreements between twomethods occur due to errors in the
manual application of the algorithm, especially for less-experienced
users. Therefore, a computerized tool and a centralized database can
signiﬁcantly reduce the potential for errors, increase reproducibility
of calculated values and histocompatibility choices, facilitate data
management, and make data analysis less labor-intensive; thus, all
these beneﬁts make EpHLA program more clinically applicable [16].
It is expected that HLAMatchmaker analysis automation will im-
prove the ability to accurately determine AMMs. We believe that
the selection of accurate AMMs will increase the number of accept-
able donors to choose for highly sensitized patients waiting for kid-
ney transplants. Identiﬁcation of matching donor/recipients pairs
based on eplets-based analysis may be the best cost–beneﬁt option
for improving organ transplantation practice because the use of
EpHLA program is fast, easy and inexpensive.
In summary, we have performed an experimental evaluation of
the EpHLA software for automated use of the HLAMatchmaker algo-
rithm. Our results demonstrate that the software is functional, reli-
able, and efﬁcient, with very good usability. Hence, we propose that
the EpHLA program can be incorporated into the daily clinical routine
of kidney and heart transplant programs to facilitate the decision-
making process especially for highly sensitized patients.6. Conclusion
The EpHLA software is an efﬁcient tool for the identiﬁcation of
acceptable mismatches for highly sensitized patients. This program
is superior to the manual use of the HLAMatchmaker algorithm
with respect to accuracy and speed of the analysis.
Acknowledgments
The work was supported by the Immunogenetics and Molecular
Biology Laboratory from UFPI. Thanks to CNPq for the scholarship
granted to Herton Luiz Alves Sales Filho. The authors acknowledge
João Batista de Oliveira Silva Jr. for corrections of the English version
of the manuscript.
References
[1] Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665–73.
[2] Patel R, Terasaki PI. Signiﬁcance of the positive crossmatch test in kidney trans-
plantation. N Engl J Med 1969;280:735–9.
[3] Bryan CF, Baier KA, Nelson PW, Luger AM, Martinez J, Pierce GE, et al. Long-term
graft survival is improved in cadaveric renal retransplantation by ﬂow cytometric
crossmatching. Transplantation 1998;66:1827–32.
[4] Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation.
Curr Opin Immunol 2009;21:573–7.
[5] Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr Opin
Immunol 2009;21:569–72.
[6] Zachary AA, Leffell MS. Barriers to successful transplantation of the sensitized
patient. Expert Rev Clin Immunol 2010;6:449–60.
[7] Claas FH, De Meester J, Witvliet MD, Smits JM, Persijn GG, Doxiadis II. Acceptable
HLA mismatches for highly immunized patients. Rev Immunogenet 1999;1:
351–8.
[8] Duquesnoy RJ. Clinical usefulness of HLAMatchmaker in HLA epitope matching for
organ transplantation. Curr Opin Immunol 2008;20:594–601.
[9] Duquesnoy RJ. A structurally based approach to determine HLA compatibility at
the humoral immune level. Hum Immunol 2006;67:847–62.
[10] Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for
histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and
HLA-DP. Hum Immunol 2007;68:12–25.
[11] Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibil-
ity determination. I. Description of the algorithm. Hum Immunol 2002;63:339–52.
[12] Valentini RP, Nehlsen-Cannarella SL, Gruber SA, Mattoo TK, West MS, Lang C, et al.
Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate
successful transplantation in highly sensitized pediatric renal allograft recipients.
Pediatr Transplant 2007;11:77–81.
[13] Campos ER, Doxiadis IIN, Temin J, Plothow A, Bellintani EC, Miyamoto Y, et al.
Proposal for a program to enhance renal transplantation opportunity for highly
sensitized patients. J Bras Transplantes 2010;13:1251–5.
[14] Haririan A, Fagoaga O, Daneshvar H, Morawski K, Sillix DH, El-Amm JM, et al. Pre-
dictive value of human leucocyte antigen epitope matching using HLAMatch-
maker for graft outcomes in a predominantly African-American renal transplant
cohort. Clin Transplant 2006;20:226–33.
[15] Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mis-
match program as a fast tool for highly sensitized patients awaiting a cadaveric
kidney transplantation: short waiting time and excellent graft outcome. Trans-
plantation 2004;78:190–3.
[16] Sousa LCDM, Sales Filho HLA, Von Glehn CQC, da Silva AS, Neto PAS, de Castro JAF.
EpHLA: an innovative and user-friendly software automating the HLAMatch-
maker algorithm for antibody analysis. Transpl Immunol 2011;25:210–6.
[17] CPRA calculator: organ procurement and transplantation network; 2011.
[18] HLAMatchmaker 2012.
[19] Pumarola T. Inﬂuence of new technologies in modern microbiology. Enferm Infecc
Microbiol Clin 2010;28(Suppl. 3):59–62.
